Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health: Enrollment Completed for Phase 3 wearABLe Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS\u00ae \u25bcin the European Economic Area, the United Kingdom, Australia and Brazil","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health Update on Abaloparatide Transdermal System","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Abaloparatide

    Menu

    Abaloparatide

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Radius Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia an...

              Details:

              Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , Australia and Brazil.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: Eladynos

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Theramex

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Radius Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

              Details:

              Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: Tymlos

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Gurnet Point Capital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition August 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Radius Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

              Details:

              The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: Tymlos

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Gurnet Point Capital

              Deal Size: $890.0 million Upfront Cash: $547.0 million

              Deal Type: Acquisition August 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Radius Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital

              Details:

              The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: Tymlos

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Gurnet Point Capital

              Deal Size: $890.0 million Upfront Cash: $547.0 million

              Deal Type: Acquisition June 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Radius Health

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Radius Health Update on Abaloparatide Transdermal System

              Details:

              The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to patients.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: Tymlos

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Radius Health

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

              Details:

              Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: BA058

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PALADIN LABS

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

              Details:

              Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: BA058

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Endo International

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Radius Health

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Radius Health: Enrollment Completed for Phase 3 wearABLe Trial

              Details:

              The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: BA058

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY